AstraZeneca (AZN: Quote,AZN.L) and Bristol-Myers Squibb Co. (BMY: Quote) Wednesday said the U.S. Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee or EMDAC recommended the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy or LD, a rare condition. LD is a group of rare syndromes often associated with severe metabolic abnormalities and significant morbidity and mortality. Patients with lipodystrophy experience a loss of fat tissue under the skin.
Help employers find you! Check out all the jobs and post your resume.
